Yes GC, crucial point for Neu is not only maximising $$ value for the asset but fast tracking to ph3’s.
Which leads me to think our discussions re our future are well advanced.
Interestingly partnering with big pharma might not be ideal or TO as Neu would not be able to drive this out come.
Ann: P2 trial shows significant improvements in Phelan-McDermid, page-206
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.71 |
Change
0.000(0.00%) |
Mkt cap ! $2.644B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 350 | $30.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.68 | 45 | 1 |
View Market Depth
| Last trade - 16.16pm 24/05/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable